PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT

NCT05772273 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Azacitidine
BIOLOGICAL: Donor lymphocyte infusion
DRUG: Camrelizumab

Sponsor

The First Affiliated Hospital of Soochow University

Collaborators

[object Object]